Dyspnea News and Research

RSS
Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.

Further Reading

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

CAM314 randomized Phase 3 clinical trial results released

CAM314 randomized Phase 3 clinical trial results released

New data from Allos Therapeutics' FOLOTYN trial for PTCL

New data from Allos Therapeutics' FOLOTYN trial for PTCL

VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics granted U.S. patent for FOLOTYN

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Swissmedic grants marketing authorization for Amitiza

Swissmedic grants marketing authorization for Amitiza

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

InterMune seeks FDA marketing approval for pirfenidone

InterMune seeks FDA marketing approval for pirfenidone

Statins may have negative effects on some cardiac patients, says study

Statins may have negative effects on some cardiac patients, says study